- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01089738
A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals
November 3, 2018 updated by: Pfizer
An Investigator And Subject-blind Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Doses Of Pf-03382792 In Healthy Elderly Subjects
This study is designed to look at the safety and blood concentrations of PF-03382792 in healthy elderly subjects after taking multiple doses for 14 days.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
To examine safety, toleratibilty and pharmacokinetics of PF-03382792 in healthy elderly subjects.
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years to 80 years (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy volunteer aged 65-80 years old
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2
- Total body weight >50 kg (110 lbs).
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- Subjects with symptoms or signs of adrenal insufficiency.
- Subjects with clinically significant ocular lens abnormalities as detected by the investigator based on the findings of a slit lamp examination performed by an ophthalmologist.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dosing
Ascending Doses
|
0.5 mg PF-03382792, qd, for 14 days or placebo
1.5 mg PF-03382792, qd, for 14 days or placebo
5 mg PF-03382792, qd, for 14 days or placebo
15 mg PF-03382792, qd, for 14 days or placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety Endpoints include: AEs, vital signs, triplicate ECGs,
Time Frame: Day 0 to Day 28
|
Day 0 to Day 28
|
Safety Endpoints include: Cosyntropin Stimulation Test, Clinical Examinations, Slit Lamp Examination, Aldosterone Concentrations
Time Frame: Day 0 to Day 28
|
Day 0 to Day 28
|
Safety Endpoints include: safety laboratory endpoints (including a complete blood count and a full chemistry panel, including electrolytes, hepatic transaminases, and urinalysis, with microscopic analysis if dipstick analysis is positive),
Time Frame: Day 0 to Day 28
|
Day 0 to Day 28
|
Pharmacokinetic endpoints include: Plasma concentrations of PF 03382792 and its N dealkylated metabolite, PF 03227077, will be measured and used to determine Cmax, Tmax, AUC on Day 1 and Css,max, Tss,max, AUC, Css,min, Css,avg on Days 7 and 14.
Time Frame: Day 0 to Day 28
|
Day 0 to Day 28
|
Additional pharmacokinetic endpoints: the accumulation ratio (Rac) will be determined from Day 14 and Day 1 AUC. If data permit, t1/2 and urinary excretion parameters (CLR for the parent and Ae and Ae%) will be calculated.
Time Frame: Day 0 to Day 28
|
Day 0 to Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2010
Primary Completion (Anticipated)
April 25, 2011
Study Completion (Anticipated)
April 25, 2011
Study Registration Dates
First Submitted
March 17, 2010
First Submitted That Met QC Criteria
March 17, 2010
First Posted (Estimate)
March 18, 2010
Study Record Updates
Last Update Posted (Actual)
November 6, 2018
Last Update Submitted That Met QC Criteria
November 3, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- B1651003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on PF-03382792 0.5mg
-
PfizerTerminated
-
Chong Kun Dang PharmaceuticalRecruitingEfficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 DiabetesType2 DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType2 DiabetesKorea, Republic of
-
Chengdu Kanghong Biotech Co., Ltd.UnknownPolypoid Choroidal Vasculopathy (PCV)China
-
Seoul St. Mary's HospitalUnknown
-
Pharmbio Korea Co., Ltd.RecruitingAcute PainKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedEfficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 DiabetesType2 DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalUnknownType2 DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalUnknownHepatitis B, ChronicKorea, Republic of
-
HK inno.N CorporationCompletedHealthyKorea, Republic of